Q-omics provides the consensus-scored ARL4A profile across patient tissues and cancer cell-line models. ARL4A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ARL4A is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, ARL4A protein abundance shows 24,853 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, KIRC, and GBM as cancer lineages where ARL4A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARL4A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARL4A survival associations across molecular data types. ARL4A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARL4A RNA expression–survival associations across cancer types. High ARL4A expression shows unfavorable associations in BLCA, ACC, KIRP, KICH and THCA, but favorable associations in KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for ARL4A RNA expression.
This table summarizes ARL4A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ARL4A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARL4A shows lower tumor expression in THCA, COAD and BRCA and higher tumor expression in KIRC, LIHC and KIRP. The KIRC box plot shows higher ARL4A RNA expression in tumor versus normal tissue (log2 FC = +1.165, t-test p < 0.001).
This table shows molecular features associated with ARL4A in patient tissues and cancer cell lines. In patient samples, ARL4A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ARL4A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
